Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

doi:10.1200/JCO.2006.08.3089

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 2007

Grever Michael R, Lucas David M, Dewald Gordon W, Neuberg Donna S, Reed John C, Kitada Shinichi, Flinn Ian W, Tallman Martin S, Appelbaum Frederick R, Larson Richard A, Paietta Elisabeth, Jelinek Diane F, Gribben John G, Byrd John C

Abstract excerpt

PURPOSE: Genomic features including unmutated immunoglobulin variable region heavy chain (IgVH) genes, del(11q22.3), del(17p13.1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome. PATIENTS AND METHODS: We prospectively evaluated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADP-ribosyl Cyclase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apoptosis

Share to Chromosome Aberrations

Share to Genes, p53

Share to Immunoglobulin Heavy Chains

Share to Immunoglobulin Variable Region

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to ZAP-70 Protein-Tyrosine Kinase

Source

Open in PubMed

Identifiers

PMID: 17283363
DOI: 10.1200/JCO.2006.08.3089

Genes

XIAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.PMID 17283363Read ↗

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.Semantic proximity Read ↗

Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.Semantic proximity Read ↗

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.Semantic proximity Read ↗

Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.Semantic proximity Read ↗

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatmentSemantic proximity Read ↗

Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).Semantic proximity Read ↗

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trialSemantic proximity Read ↗

TP53 mutation and survival in chronic lymphocytic leukemia.Semantic proximity Read ↗

Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.Semantic proximity Read ↗

Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.Semantic proximity Read ↗

Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel DrugsSemantic proximity Read ↗

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.